GILD - Why Is Gilead Sciences Stock Trading Lower Today? | Benzinga
Gilead Sciences Inc (NASDAQ:GILD) said it paused tumor study enrollment.
The Food and Drug Administration (FDA) subsequently requested a partial clinical hold on these trials.
Gilead is reviewing the benefit-risk of magrolimab across all ongoing trials and will provide an update on this assessment as soon as possible.
Patients already enrolled in the Gilead-sponsored ELEVATE solid tumor studies and deriving clinical benefit may continue to choose receiving magrolimab following reconsenting to the study with their healthcare provider.
The Gilead-sponsored ELEVATE solid tumor studies impacted by the partial clinical hold include Phase 2 studies in:
- Head and ...